Jasper Therapeutics Advances with Asthma Clinical Trials
Jasper Therapeutics, Inc. (NASDAQ: JSPR), an innovative biotechnology company in the clinical stage, is making notable progress in its efforts to transform treatments for chronic illnesses. The company recently received approval for its Clinical Trial Application (CTA) from Health Canada, allowing it to begin a significant Phase 1b/2a clinical trial for its groundbreaking therapy, briquilimab, aimed at managing asthma.
Exploring Briquilimab and Its Promise
Briquilimab is a targeted monoclonal antibody that focuses on the c-Kit (CD117) receptor, which plays an important role in various conditions driven by mast cells. This pioneering therapy aims to address diseases like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma itself. The approval from Health Canada is a critical milestone in briquilimab's development, highlighting its potential in treating asthma through a focused clinical challenge study.
Initiation of the Clinical Trial
Edwin Tucker, M.D., Chief Medical Officer of Jasper, shared that the company is excited to start the enrollment process for the asthma study shortly. This trial will be conducted as a double-blind, placebo-controlled study, involving 30 patients across 10 locations in Canada and the EU. A key aim of this trial is to establish proof of concept for briquilimab, which will guide future research into broader asthma patient populations.
Research and Development Objectives
The trial plans to administer a single dose of 180mg of briquilimab, focusing on evaluating mast cell depletion and recovery, along with safety and changes in airway responsiveness. Patient dosing is expected to commence in the fourth quarter of 2024, with initial results anticipated to be released in the latter half of 2025. Following the CTA clearance, Ronald Martell, President and CEO, emphasized the importance of this achievement in advancing their pipeline targeting diseases driven by mast cells.
Briquilimab's Effectiveness and Ongoing Investigations
A standout feature of briquilimab is its capability to effectively deplete mast cells, thereby inhibiting the inflammatory responses commonly associated with allergic reactions, including asthma. This targeted strategy aims to showcase the treatment's durability and effectiveness in clinical environments. To date, briquilimab has demonstrated a positive safety and efficacy profile among over 145 participants in various studies, addressing conditions ranging from severe combined immunodeficiency (SCID) to acute myeloid leukemia (AML).
The Jasper c-Kit Mouse™ Model
Furthermore, Jasper Therapeutics has announced that it has secured a registered trademark for its proprietary model, the Jasper c-Kit Mouse™. This model allows for direct testing of c-Kit inhibitors, enabling researchers to investigate their potential across different diseases while overcoming the limitations found in standard models. Wendy Pang, M.D., Ph.D., noted that this unique capability enhances clinical translatability in preclinical studies, giving Jasper a strategic advantage as it broadens its research opportunities.
Dedication to Innovation
Jasper Therapeutics is dedicated to advancing briquilimab for diseases that significantly impact patients' quality of life. Their focus on innovative treatment approaches underscores the company's ambition to lead in the biotechnology sector, particularly in relation to mast cell-driven conditions. As they gear up for new clinical trials, Jasper continues to strengthen its pipeline, aiming for wide applicability across various diseases.
Frequently Asked Questions
What is briquilimab used for?
Briquilimab is a monoclonal antibody under development for treating mast cell-driven conditions, including asthma, chronic spontaneous urticaria, and chronic inducible urticaria.
How many patients will be involved in the asthma study?
The Phase 1b/2a asthma study is set to enroll 30 patients across several sites in Canada and the EU.
What is the purpose of the Jasper c-Kit Mouse™ model?
The Jasper c-Kit Mouse™ model is designed to facilitate the direct testing of c-Kit inhibitors, providing vital insights into treatment efficacy across various diseases.
When is the expected start date for patient dosing?
Patient dosing for the asthma trial is projected to begin in the fourth quarter of 2024.
What are the goals of the clinical trial?
The primary objective is to establish proof of concept for briquilimab’s effectiveness in depleting mast cells in asthma and to assess its safety in a clinical setting.